MedTrace Logo

Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis

NCT03478033 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2018-04-24

No results posted yet for this study

Summary

To compared the efficacy and safety of rifampicin and rifabutin which included in the standard treatment of anti-tuberculosis in HIV/AIDs patients combined with pulmonary tuberculosis, a multi-center, prospective cohort will be established. Antiviral efficacy and drug drug interaction will be investigated in order to provide optimized treatment for HIV/AIDs with tuberculosis.

Conditions

  • Tuberculosis, Pulmonary
  • AIDS

Interventions

DRUG

Rifampicin

Rifampicin capsules, 150mg

DRUG

Rifabutin

Rifabutin capsules, 150mg

Sponsors & Collaborators

  • The Guangxi Zhuang Autonomous Region Longtan hospital

    collaborator UNKNOWN

  • The Fourth People's Hospital of Nanning

    collaborator OTHER

  • Shenzhen Third People's Hospital

    collaborator OTHER

  • Yunnan Provincial Infectious Disease Hospital

    collaborator OTHER

  • Zhejiang University

    collaborator OTHER

  • Chongqing Public Health Medical Center

    collaborator OTHER

  • Shanghai Public Health Clinical Center

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-15
Primary Completion
2020-06-01
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03478033 on ClinicalTrials.gov